Adrenal incidentalomas — a continuing management dilemma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Adrenal incidentalomas (AI), adrenal tumors detected through an imaging procedure done for reasons unrelated to adrenal dysfunction, is becoming a common clinical problem with the more frequent utilization of different imaging techniques. Most such tumors are benign and hormonally inactive. A variety of diagnostic strategies have been developed to distinguish the latter; however, they are still controversial. Even after a commissioned systematic review of the literature and a state of the science conference sponsored by the National Institutes of Health, the optimal strategy for hormonal screening of a patient with AI is unknown, but we anticipate further refinements and major advances in the field. Surgery is the ultimate solution for the diagnostic-therapeutic dilemma of AI. Careful planning is required, and the learning curve which influences clinical decision making is especially relevant to immediate outcomes. The benefit of making a diagnosis of a clinically significant AI must be considered in the context of the patient’s overall condition and preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781 · cited 5×
“This issue has gained increasing attention (Mansmann et al. 2004), and several approaches have been recommended including strategies for hormonal screening, radiologic testing, and histopathologic examination.”
BackgroundInfluentialCharacterization of adrenal masses using unenhanced CT: an analysis of the CT literature
Boland, G. W., Lee, M. J., Gazelle, G. S., Halpern, E. F., McNicholas, M. M., & Mueller, P. R. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.1.9648789 · Cited by 693
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
Pacak, K., Linehan, W. M., Eisenhofer, G., Walther, M. M., & Goldstein, D. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00016 · Cited by 618
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Tauchmanovà, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.-A., Fazio, S., & Lombardi, G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011766 · Cited by 400 · cited 1×
“Tauchmanova et al. (2002) used the criteria of the National Italian Group on Adrenal Tumors (AI-SIE) for SAGH: absence of clinical signs of cortisol excess and two abnormalities in the regulation of the HPA axis; failure to suppress serum cortisol to less than 83 nmol/l (3mg/dl) by 2mg…”
MethodCT time-attenuation washout curves of adrenal adenomas and nonadenomas
Korobkin, M., Brodeur, F. J., Francis, I. R., Quint, L. E., Dunnick, N. R., & Londy, F. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.3.9490968 · Cited by 386 · cited 1×
“(Korobkin et al. 1996, 1998, Boland et al. 1997, 1998, Caoili et al. 2000, 2002).”
Delayed enhanced CT of lipid-poor adrenal adenomas
Caoili, E. M., Korobkin, M., Francis, I. R., Cohan, R. H., & Dunnick, N. R. (2000) · American Journal of Roentgenology · doi:10.2214/ajr.175.5.1751411 · Cited by 305 · cited 1×
“(Korobkin et al. 1996, 1998, Boland et al. 1997, 1998, Caoili et al. 2000, 2002).”
Subclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285 · cited 2×
“…of the reduction in catecholamine levels that follow pheochromocytoma extirpation or the risk of secondary adrenal insufficiency after the removal of an AI with clinical or subclinical autonomous cortisol hypersecretion where of the HPA axis is suppressed (Reincke et al. 1992, Reincke 2000).”
BackgroundAngeli, A., Osella, G., Ali, A., & Terzolo, M. (1997) · Hormone Research · doi:10.1159/000185477 · Cited by 259 · cited 2×
“Large size, irregular shapes, vague contour, invasion into surrounding structures and high signal intensity usually denote malignancy (Angeli et al. 1997).”
BackgroundLong-term follow-up study of patients with adrenal incidentalomas.
Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470489 · Cited by 215 · cited 1×
“About 5–25% increase in size by at least 1 cm and 3–4% decrease (Jockenhovel et al. 1992, Kasperlik-Zeluska et al. 1997, Barzon et al. 1999, 2002, Siren et al. 2000, Grossrubatscher et al. 2001, Lau et al. 2002, Libe et al. 2002).”
BackgroundSubclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198 · cited 2×
“…of adrenomedullary function, with the dexamethasone suppression test being the standard evaluation for subclinical autonomous cortisol hypersecretion; because pituitary ACTH-dependent hypercortisolism is not expected, the issue of false-negative tests is of much less concern (Terzolo et al. 1998).”
BackgroundThe molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors
Koch, C. A., Pacak, K., & Chrousos, G. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021069 · Cited by 177 · cited 3×
“…and a novel neuroendocrine marker for chromaffin cell tumor, have not www.endocrinology-journals.org 591Downloaded from Bioscientifica.com at 12/08/2018 07:51:37AM via free access been reliable for distinguishing between benign and malignant tumors (Kolomecki et al. 2001a,b, Koch et al. 2002a).”
BackgroundDevelopment of overt Cushing’s syndrome in patients with adrenal incidentaloma
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460061 · Cited by 162 · cited 2×
“About 5–25% increase in size by at least 1 cm and 3–4% decrease (Jockenhovel et al. 1992, Kasperlik-Zeluska et al. 1997, Barzon et al. 1999, 2002, Siren et al. 2000, Grossrubatscher et al. 2001, Lau et al. 2002, Libe et al. 2002).”
BackgroundMethodIncidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients
Kasperlik‐Załuska, A. A., Rosłonowska, E., Słowińska‐Srzednicka, J., Migdalska, B., Jeske, W., Makowska, A., & Snochowska, H. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1751.x · Cited by 155 · cited 1×
“About 5–25% increase in size by at least 1 cm and 3–4% decrease (Jockenhovel et al. 1992, Kasperlik-Zeluska et al. 1997, Barzon et al. 1999, 2002, Siren et al. 2000, Grossrubatscher et al. 2001, Lau et al. 2002, Libe et al. 2002).”
BackgroundDiagnosis and differential diagnosis of Cushing’s syndrome
Findling, J. W., & Raff, H. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70209-7 · Cited by 147 · cited 7×
“In addition, the natural course of patients with SAGH is unknown.”
BackgroundInfluentialEMRAL, R., UYSAL, A. R., ASIK, M., GULLU, S., CORAPCIOGLU, D., TONYUKUK, V., & ERDOGAN, G. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.399 · Cited by 104 · cited 1×
“However, these metabolic abnormalities may improve after removal of the AI (Emral et al. 2003).”
BackgroundAdrenal adenoma and hypertension
Kokko, J. P., Brown, T., & Berman, M. (1967) · The Lancet · doi:10.1016/s0140-6736(67)91092-6 · Cited by 101
Torlontano, M., Chiodini, I., Pileri, M., Guglielmi, G., Cammisa, M., Modoni, S., Carnevale, V., Trischitta, V., & Scillitani, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5856 · Cited by 91
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Mantero, F., & Arnaldi, G. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70119-5 · Cited by 83 · cited 1×
“9 years (Mantero & Arnaldi 2000).”
Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli, N., Catargi, B., Ronci, N., Vergnot, V, Leccia, F., Ferriere, J., Chene, G., Grenier, N., Laurent, F., & Tabarin, A. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440401 · Cited by 83 · cited 1×
“In contrast, Valli et al. (2001) found that unsuppressed 8 am cortisol after overnight dexamethasone suppression had 100% sensitivity and 67% specificity to predict unilateral uptake.”
BackgroundChiodini, I., Guglielmi, G., Battista, C., Carnevale, V., Torlontano, M., Cammisa, M., Trischitta, V., & Scillitani, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031413 · Cited by 82 · cited 1×
“In a recent study, involving 70 women with AI and 84 controls, evaluated by qualitative CT, the prevalence of vertebral fractures in pre- and postmenopausal AI patients, was significantly higher than in controls (Chiodini et al. 2004).”
Tauchmanova, L., Rossi, R., Nuzzo, V, del Puente, A., Esposito-del Puente, A., Pizzi, C., Fonderico, F., Lupoli, G., & Lombardi, G. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450241 · Cited by 79 · cited 1×
“Abnormalities in bone turnover and bone mass have been reported as well (Torlontano et al. 1999, Tauchmanova et al. 2001, Francucci et al. 2002).”
BackgroundTsagarakis, S., Roboti, C., Kokkoris, P., Vasiliou, V., Alevizaki, C., & Thalassinos, N. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00509.x · Cited by 75 · cited 1×
“Tsagarakis et al. (1998) performed the dexamethasone suppression test in 61 patients with incidentally discovered adrenal masses.”
MethodBardet, S., Rohmer, V., Murat, A., Guillemot, C., Maréchaud, R., Chupin, M., Lecomte, P., Simon, D., Delemer, B., Schneebelli, S., et al. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.720541.x · Cited by 71
Reznik, Y., Lefebvre, H., Rohmer, V., Charbonnel, B., Tabarin, A., Rodien, P., Lecomte, P., Bardet, S., Coffin, C., & Mahoudeau, J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02048.x · Cited by 71 · cited 1×
“Even more recently, in a prospective clinical study, Reznik et al. (2004) were able to detect aberrant membrane receptors by in vivo stimulation tests in autonomously functioning unilateral adrenocortical adenomas, and they concluded that these receptors may be involved in the modulation of…”
Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65 · cited 1×
“Abnormalities in bone turnover and bone mass have been reported as well (Torlontano et al. 1999, Tauchmanova et al. 2001, Francucci et al. 2002).”
BackgroundPrimary aldosteronism in normokalemic patients with adrenal incidentalomas
Bernini, G., Moretti, A., Argenio, G., & Salvetti, A. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460523 · Cited by 64
The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.
Grossrubatscher, E., Vignati, F., Possa, M., & Loli, P. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343941 · Cited by 52 · cited 1×
“About 5–25% increase in size by at least 1 cm and 3–4% decrease (Jockenhovel et al. 1992, Kasperlik-Zeluska et al. 1997, Barzon et al. 1999, 2002, Siren et al. 2000, Grossrubatscher et al. 2001, Lau et al. 2002, Libe et al. 2002).”
Background
Cited by
Diagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
Patel, J., Davenport, M. S., Cohan, R. H., & Caoili, E. M. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9620 · Cited by 119
“Because pheochromocytomas can be both clinically significant and clinically silent [18, 19], the ability to differentiate pheochromocytoma from adrenal adenoma is a worthwhile goal.”
BackgroundMechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review
Chiodini, I., Vainicher, C. E., Morelli, V, Palmieri, S., Cairoli, E., Salcuni, A. S., Copetti, M., & Scillitani, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0289 · Cited by 73
Clinical characteristics for 348 patients with adrenal incidentaloma
Kim, J., Bae, K. H., Choi, Y. K., Jeong, J. Y., Park, K. G., Kim, J. G., & Lee, I. K. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.1.20 · Cited by 72
Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Metadata
- Authors
- Nawar, R., & Aron, D.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2005-09
- Volume
- 12
- Issue
- 3
- Pages
- 585-598
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2165887899
- Cited by
- 55
- References
- 30
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.